NASDAQ:ARQT Arcutis Biotherapeutics (ARQT) Stock Forecast, Price & News $5.51 -0.07 (-1.25%) (As of 03:40 PM ET) Add Compare Share Share Today's Range$5.33▼$5.7050-Day Range$5.38▼$10.9152-Week Range$5.19▼$20.64Volume868,726 shsAverage Volume1.09 million shsMarket Capitalization$339.69 millionP/E RatioN/ADividend YieldN/APrice Target$43.43 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Arcutis Biotherapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside698.3% Upside$43.43 Price TargetShort InterestBearish29.68% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.49Based on 7 Articles This WeekInsider TradingSelling Shares$11,299 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.77) to ($3.92) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.80 out of 5 starsMedical Sector804th out of 975 stocksPharmaceutical Preparations Industry376th out of 456 stocks 3.5 Analyst's Opinion Consensus RatingArcutis Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $43.43, Arcutis Biotherapeutics has a forecasted upside of 698.3% from its current price of $5.44.Amount of Analyst CoverageArcutis Biotherapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted29.68% of the float of Arcutis Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverArcutis Biotherapeutics has a short interest ratio ("days to cover") of 13.1, which indicates bearish sentiment.Change versus previous monthShort interest in Arcutis Biotherapeutics has recently increased by 6.41%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArcutis Biotherapeutics does not currently pay a dividend.Dividend GrowthArcutis Biotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARQT. Previous Next 1.9 News and Social Media Coverage News SentimentArcutis Biotherapeutics has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Arcutis Biotherapeutics this week, compared to 3 articles on an average week.Search InterestOnly 8 people have searched for ARQT on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Arcutis Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcutis Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,299.00 in company stock.Percentage Held by Insiders20.70% of the stock of Arcutis Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arcutis Biotherapeutics are expected to grow in the coming year, from ($4.77) to ($3.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcutis Biotherapeutics is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcutis Biotherapeutics is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcutis Biotherapeutics has a P/B Ratio of 1.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Arcutis Biotherapeutics (NASDAQ:ARQT) StockArcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Read More ARQT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARQT Stock News HeadlinesSeptember 27, 2023 | finance.yahoo.comRoivant Sciences Ltd. (ROIV) Moves 21.6% Higher: Will This Strength Last?September 27, 2023 | finance.yahoo.comArcutis Appoints L. Todd Edwards as Chief Commercial OfficerSeptember 28, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 26, 2023 | americanbankingnews.comArcutis Biotherapeutics (NASDAQ:ARQT) Receives Buy Rating from MizuhoSeptember 26, 2023 | finance.yahoo.comMizuho reaffirms 'Buy' recommendation for Arcutis Biotherapeutics, amidst mixed institutional sentimentSeptember 21, 2023 | americanbankingnews.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives $44.75 Average PT from AnalystsSeptember 19, 2023 | markets.businessinsider.comArcutis Biotherapeutics Reveals Promising Data From Lead Drug In Pediatric Patients With Atopic DermatitisSeptember 19, 2023 | msn.comArcutis posts late-stage win for atopic dermatitis therapy in childrenSeptember 28, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 19, 2023 | markets.businessinsider.comGoldman Sachs Sticks to Its Buy Rating for Arcutis Biotherapeutics (ARQT)September 19, 2023 | finance.yahoo.comArcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5September 13, 2023 | markets.businessinsider.comJonesTrading Reaffirms Their Buy Rating on Arcutis Biotherapeutics (ARQT)September 13, 2023 | finance.yahoo.comArcutis (ARQT) Files sNDA for Zoryve in Atopic Dermatitis, Stock UpSeptember 12, 2023 | finance.yahoo.comArcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and OlderSeptember 7, 2023 | markets.businessinsider.comArcutis Reports Results From INTEGUMENT-OLE Long-term Extension Trial Of Roflumilast Cream 0.15%September 7, 2023 | finance.yahoo.comWhy Shares of Arcutis Biotherapeutics Fell This WeekSeptember 7, 2023 | finance.yahoo.comArcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)August 31, 2023 | finance.yahoo.comArcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) ReportAugust 29, 2023 | finance.yahoo.comArcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%August 23, 2023 | markets.businessinsider.comJonesTrading Sticks to Their Buy Rating for Arcutis Biotherapeutics (ARQT)August 19, 2023 | finanznachrichten.deArcutis Biotherapeutics, Inc.: Arcutis Appoints Interim Chief Financial Officer (CFO)August 18, 2023 | msn.comArcutis CFO Scott Burrows to leave the companyAugust 18, 2023 | finance.yahoo.comArcutis Appoints Interim Chief Financial Officer (CFO)August 13, 2023 | finance.yahoo.comBroker Revenue Forecasts For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging HigherAugust 11, 2023 | finance.yahoo.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported, And Analysts Assigned A US$41.57 Price TargetAugust 11, 2023 | msn.comTD Cowen Maintains Arcutis Biotherapeutics (ARQT) Outperform RecommendationAugust 11, 2023 | markets.businessinsider.com7 Analysts Have This to Say About Arcutis BiotherapeuticsSee More Headlines Receive ARQT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ARQT Company Calendar Last Earnings8/08/2023Today9/28/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARQT CUSIPN/A CIK1787306 Webwww.arcutis.com Phone805-418-5006FaxN/AEmployees268Year Founded2016Price Target and Rating Average Stock Price Forecast$43.43 High Stock Price Forecast$57.00 Low Stock Price Forecast$22.00 Forecasted Upside/Downside+681.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($5.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-311,460,000.00 Net Margins-2,837.94% Pretax Margin-2,837.94% Return on Equity-188.88% Return on Assets-79.79% Debt Debt-to-Equity Ratio2.48 Current Ratio8.43 Quick Ratio8.14 Sales & Book Value Annual Sales$3.69 million Price / Sales92.89 Cash FlowN/A Price / Cash FlowN/A Book Value$3.44 per share Price / Book1.62Miscellaneous Outstanding Shares61,650,000Free Float48,892,000Market Cap$342.77 million OptionableNot Optionable Beta0.64 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Todd Franklin Watanabe M.A. (Age 55)Pres, CEO & Director Comp: $1.01MDr. Bhaskar Chaudhuri Ph.D. (Age 68)Co-Founder & Independent Director Comp: $59.67kMr. Masaru Matsuda Esq. (Age 52)J.D., Sr. VP, Gen. Counsel & Corp. Sec. Comp: $626.22kDr. Patrick E. Burnett M.D. (Age 51)Ph.D., Sr. VP & Chief Medical Officer Comp: $689.95kMr. John W. Smither CPA (Age 70)Interim CFO & Principal Accounting Officer Ms. Patricia A. Turney (Age 56)Sr. VP of Operations Mr. Rajvir MadanChief Digital & Technology OfficerMr. Eric McIntyreHead of Investor RelationsMs. Courtney Barton (Age 40)VP and Chief Compliance Officer & Privacy Officer Ms. Amanda SheldonHead of Corp. CommunicationsMore ExecutivesKey CompetitorsAldeyra TherapeuticsNASDAQ:ALDXARS PharmaceuticalsNASDAQ:SPRYPrecigenNASDAQ:PGENCOMPASS PathwaysNASDAQ:CMPSSIGA TechnologiesNASDAQ:SIGAView All CompetitorsInsiders & InstitutionsBarclays PLCSold 1,096,647 shares on 9/21/2023Ownership: 0.379%Perceptive Advisors LLCBought 300,000 shares on 8/24/2023Ownership: 0.000%Patrick BurnettSold 1,605 sharesTotal: $11,299.20 ($7.04/share)California State Teachers Retirement SystemBought 1,817 shares on 8/21/2023Ownership: 0.089%Nuveen Asset Management LLCBought 108,935 shares on 8/16/2023Ownership: 0.345%View All Insider TransactionsView All Institutional Transactions ARQT Stock - Frequently Asked Questions Should I buy or sell Arcutis Biotherapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcutis Biotherapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARQT shares. View ARQT analyst ratings or view top-rated stocks. What is Arcutis Biotherapeutics' stock price forecast for 2023? 6 brokerages have issued twelve-month target prices for Arcutis Biotherapeutics' shares. Their ARQT share price forecasts range from $22.00 to $57.00. On average, they predict the company's share price to reach $43.43 in the next twelve months. This suggests a possible upside of 681.1% from the stock's current price. View analysts price targets for ARQT or view top-rated stocks among Wall Street analysts. How have ARQT shares performed in 2023? Arcutis Biotherapeutics' stock was trading at $14.80 at the beginning of the year. Since then, ARQT shares have decreased by 62.4% and is now trading at $5.56. View the best growth stocks for 2023 here. Are investors shorting Arcutis Biotherapeutics? Arcutis Biotherapeutics saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 13,280,000 shares, an increase of 6.4% from the August 31st total of 12,480,000 shares. Based on an average trading volume of 1,010,000 shares, the days-to-cover ratio is presently 13.1 days. Approximately 29.7% of the shares of the company are sold short. View Arcutis Biotherapeutics' Short Interest. When is Arcutis Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our ARQT earnings forecast. How were Arcutis Biotherapeutics' earnings last quarter? Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) issued its earnings results on Tuesday, August, 8th. The company reported ($1.16) EPS for the quarter, topping analysts' consensus estimates of ($1.22) by $0.06. The business earned $5.19 million during the quarter, compared to the consensus estimate of $4.87 million. Arcutis Biotherapeutics had a negative net margin of 2,837.94% and a negative trailing twelve-month return on equity of 188.88%. What ETF holds Arcutis Biotherapeutics' stock ? Virtus LifeSci Biotech Clinical Trials ETF holds 10,172 shares of ARQT stock, representing 0.89% of its portfolio. What other stocks do shareholders of Arcutis Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcutis Biotherapeutics investors own include Black Diamond Therapeutics (BDTX), Pfizer (PFE), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Applied Therapeutics (APLT), Aptinyx (APTX), BioNTech (BNTX), ServiceNow (NOW), Qualys (QLYS) and AbbVie (ABBV). When did Arcutis Biotherapeutics IPO? (ARQT) raised $125 million in an initial public offering (IPO) on Friday, January 31st 2020. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO and Cantor was co-manager. What is Arcutis Biotherapeutics' stock symbol? Arcutis Biotherapeutics trades on the NASDAQ under the ticker symbol "ARQT." Who are Arcutis Biotherapeutics' major shareholders? Arcutis Biotherapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include State Street Corp (8.48%), Rubric Capital Management LP (7.92%), Jennison Associates LLC (6.99%), BlackRock Inc. (6.86%), Polar Capital Holdings Plc (5.07%) and Marshall Wace LLP (3.76%). Insiders that own company stock include Bhaskar Chaudhuri, David W Osborne, Howard G Welgus, Howard G Welgus, John W Smither, Masaru Matsuda, Orbimed Advisors Llc, Patricia A Turney, Patrick Burnett, Scott L Burrows and Todd Franklin Watanabe. View institutional ownership trends. How do I buy shares of Arcutis Biotherapeutics? Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Arcutis Biotherapeutics' stock price today? One share of ARQT stock can currently be purchased for approximately $5.56. How much money does Arcutis Biotherapeutics make? Arcutis Biotherapeutics (NASDAQ:ARQT) has a market capitalization of $342.77 million and generates $3.69 million in revenue each year. The company earns $-311,460,000.00 in net income (profit) each year or ($5.54) on an earnings per share basis. How many employees does Arcutis Biotherapeutics have? The company employs 268 workers across the globe. How can I contact Arcutis Biotherapeutics? Arcutis Biotherapeutics' mailing address is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. The official website for the company is www.arcutis.com. The company can be reached via phone at 805-418-5006 or via email at ir@arcutis.com. This page (NASDAQ:ARQT) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.